Skip to content
DETOUR
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
PAD
PAD
DETOUR System
DETOUR System Evidence
DETOUR System Resources
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFU’s
About Us
About Us
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator Initiated
Research
Contact Us
DETOUR
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
PAD
PAD
DETOUR System
DETOUR System Evidence
DETOUR System Resources
AAA
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFU’s
About Us
About Us
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator Initiated
Research
Contact Us
Search
Read about Endologix
in the news
Embrace the evidence.
The Latest:
Jul 9
Endologix Announces that Scott Huennekens Joins Board of Directors
See Release
All News
Archives
All
2026
2025
2024
2023
2022
2021
Jul 9
Endologix Announces that Scott Huennekens Joins Board of Directors
Mar 20
Endologix Announces 1000 patients treated with the DETOUR™ System.
Mar 3
Endologix Appoints Andrew Davis as Chief Commercial Officer
Jan 7
Endologix Announces Leadership Transition
Nov 5
Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session
Previous
Page
1
Page
2
Page
3
Page
4
Page
5
Next
